Literature DB >> 11032416

Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length.

Z Lai1, K R Auger, C M Manubay, R A Copeland.   

Abstract

Upon exposure to DNA-damaging agents, the p53 tumor suppressor protein is stabilized and activated, leading to cell cycle arrest, DNA repair, or apoptosis. One of the major factors that regulates the level and the transcriptional activity of p53 is the hdm2 oncoprotein. hdm2 binds to the N-terminal transactivation domain of p53 to block the transcriptional activity of p53 directly. hdm2 also functions as the E3 ligase that ubiquitinates p53 for proteasome degradation. Fluorescence anisotropy was employed to measure directly the binding of hdm2(1-126) to a p53 N-terminal peptide labeled with Oregon Green (an analogue of fluorescein). Phosphorylation of Ser15 and Ser2O did not affect the binding of the p53 peptide to hdm2. Thrl8 phosphorylation, on the other hand, reduced the binding by at least 20-fold. This suggests that phosphorylation of Thr18 could be a regulatory mechanism that disrupts the hdm2-p53 complex, thus activating p53 in response to DNA damage. The effect of p53 peptide length on binding to hdm2 was also measured quantitatively. Interestingly, p53(18-26) exhibits 10-fold higher affinity to hdm2 than do longer peptides (20- or 35-mer). This result may reflect a strong entropic barrier to binding for the longer peptides.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032416     DOI: 10.1006/abbi.2000.1998

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  23 in total

1.  Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.

Authors:  Mark A McCoy; Jennifer J Gesell; Mary M Senior; Daniel F Wyss
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

2.  Limitations of peptide retro-inverso isomerization in molecular mimicry.

Authors:  Chong Li; Marzena Pazgier; Jing Li; Changqing Li; Min Liu; Guozhang Zou; Zhenyu Li; Jiandong Chen; Sergey G Tarasov; Wei-Yue Lu; Wuyuan Lu
Journal:  J Biol Chem       Date:  2010-04-09       Impact factor: 5.157

3.  Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2.

Authors:  Elin Hallan Naderi; Aart G Jochemsen; Heidi Kiil Blomhoff; Soheil Naderi
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

4.  Beta-peptides with improved affinity for hDM2 and hDMX.

Authors:  Elizabeth A Harker; Douglas S Daniels; Danielle A Guarracino; Alanna Schepartz
Journal:  Bioorg Med Chem       Date:  2009-01-23       Impact factor: 3.641

5.  Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.

Authors:  Zhihong Lai; Tao Yang; Young B Kim; Thais M Sielecki; Melody A Diamond; Peter Strack; Mark Rolfe; Maureen Caligiuri; Pamela A Benfield; Kurt R Auger; Robert A Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-29       Impact factor: 11.205

6.  It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.

Authors:  Ian M Love; Steven R Grossman
Journal:  Genes Cancer       Date:  2012-03

7.  A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues.

Authors:  Lata T Gooljarsingh; Christine Fernandes; Kang Yan; Hong Zhang; Michael Grooms; Kyung Johanson; Robert H Sinnamon; Robert B Kirkpatrick; John Kerrigan; Tia Lewis; Marc Arnone; Alastair J King; Zhihong Lai; Robert A Copeland; Peter J Tummino
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

8.  A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2.

Authors:  Karim M ElSawy; Adelene Sim; David P Lane; Chandra S Verma; Leo Sd Caves
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2.

Authors:  D P Teufel; M Bycroft; A R Fersht
Journal:  Oncogene       Date:  2009-04-13       Impact factor: 9.867

10.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.